Tetanus immunoglobulin: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Intramuscular
Passive immunisation against tetanus

Adult: Prophylaxis: 250 units, increased to 500 units if >24 hr have elapsed or following burns or there is risk of heavy contamination. Treatment: 3,000-6,000 units given by inj into multiple sites.
Child: Prophylaxis: 250 units, increased to 500 units if >24 hr have elapsed or following burns or there is risk of heavy contamination. Treatment: 3,000-6,000 units given by inj into multiple sites.

Special Precautions

Caution when used in patients with coagulation disorders or thrombocytopenia. Not to be used for IV admin. Pregnancy, lactation. If adsorbed tetanus vaccine is to be used concurrently, the vaccine and immunoglobulin should be administered with separate syringes and into different inj sites with separate lymphatic drainage. Patients should be observed for at least 20 minutes after admin.

Adverse Reactions

Inj-site reactions: Pain, soreness and tenderness. Increased temperature, angioneurotic oedema, nephritic syndrome, anaphylactic shock.

Pregnancy Category (US FDA)

IM/Parenteral: C

Drug Interactions

May reduce the efficacy of live vaccines.

Action

Description: Tetanus immunoglobulin is used for passive immunisation against tetanus.
Pharmacokinetics:
Absorption: Well absorbed.

Storage

Store at 2-8°C. Do not freeze.

MIMS Class

Vaccines, Antisera & Immunologicals

Disclaimer: This information is independently developed by MIMS based on Tetanus immunoglobulin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com